TY - JOUR
T1 - Treatment of Executive Function Deficits in autism spectrum disorder with repetitive transcranial magnetic stimulation
T2 - A double-blind, sham-controlled, pilot trial
AU - Ameis, Stephanie H.
AU - Blumberger, Daniel M.
AU - Croarkin, Paul E.
AU - Mabbott, Donald J.
AU - Lai, Meng Chuan
AU - Desarkar, Pushpal
AU - Szatmari, Peter
AU - Daskalakis, Zafiris J.
N1 - Funding Information:
This publication was made possible through the American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award for Child and Adolescent Psychiatry Residents and Junior Faculty (to SHA), supported by CFAK; its contents are the responsibility of the authors and do not necessarily reflect the official views of AACAP. This research was also supported by: the University of Toronto, Faculty of Medicine, Dean's Fund New Staff Grant, the Innovation Fund from the Alternate Funding Plan of the Academic Health Sciences Centres of Ontario, an Ontario Mental Health Foundation (OMHF) Project A Grant and New Investigator Fellowship (to SHA). SHA receives support from the Canadian Institutes of Health Research (CIHR), and the National Institutes of Mental Health (NIMH). SHA and M-CL are supported by the O'Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Centre for Addiction and Mental Health (CAMH),The Hospital for Sick Children and University of Toronto, the Slaight Family Child and Youth Mental Health Innovation Fund and The Catherine and Maxwell Meighen Foundation (both via CAMH Foundation). This work was also supported in part by an Academic Scholars Award from the Department of Psychiatry, University of Toroto (to SHA and M-CL). M-CL is also supported by the Ontario Brain Institute via the Province of Ontario Neurodevelopmental Disorders (POND) Network. DMB receives research support from CIHR, NIH, Brain Canada and the Temerty Family Foundation through the CAMH Foundation and the Campbell Family Mental Health Research Institute. ZJD was supported by the OMHF, CIHR, NIMH and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health Foundation and the Campbell Institute. PEC was supported by R01 MH113700. The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. PS is supported by the Patsy and Jamie Anderson in Child and Youth Mental Health. PD is currently supported by Scottish Rite Charitable Foundation of Canada Research Grant and Caskey/Francis Clinical Research Award.
Funding Information:
This publication was made possible through the American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award for Child and Adolescent Psychiatry Residents and Junior Faculty (to SHA), supported by CFAK ; its contents are the responsibility of the authors and do not necessarily reflect the official views of AACAP. This research was also supported by: the University of Toronto, Faculty of Medicine, Dean’s Fund New Staff Grant , the Innovation Fund from the Alternate Funding Plan of the Academic Health Sciences Centres of Ontario , an Ontario Mental Health Foundation (OMHF) Project A Grant and New Investigator Fellowship (to SHA). SHA receives support from the Canadian Institutes of Health Research (CIHR) , and the National Institutes of Mental Health (NIMH) . SHA and M-CL are supported by the O’Brien Scholars Program within the Child and Youth Mental Health Collaborative at the Centre for Addiction and Mental Health (CAMH), The Hospital for Sick Children and University of Toronto , the Slaight Family Child and Youth Mental Health Innovation Fund and The Catherine and Maxwell Meighen Foundation (both via CAMH Foundation). This work was also supported in part by an Academic Scholars Award from the Department of Psychiatry, University of Toroto (to SHA and M-CL). M-CL is also supported by the Ontario Brain Institute via the Province of Ontario Neurodevelopmental Disorders (POND) Network . DMB receives research support from CIHR , NIH , Brain Canada and the Temerty Family Foundation through the CAMH Foundation and the Campbell Family Mental Health Research Institute . ZJD was supported by the OMHF , CIHR , NIMH and the Temerty Family and Grant Family and through the Centre for Addiction and Mental Health Foundation and the Campbell Institute . PEC was supported by R01 MH113700 . The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. PS is supported by the Patsy and Jamie Anderson in Child and Youth Mental Health . PD is currently supported by Scottish Rite Charitable Foundation of Canada Research Grant and Caskey/Francis Clinical Research Award .
Publisher Copyright:
© 2020
PY - 2020/5/1
Y1 - 2020/5/1
N2 - Background: In youth and young adults with autism spectrum disorder (ASD), executive function (EF) deficits may be a promising treatment target with potential impact on everyday functioning. Objective: To conduct a pilot randomized, double-blind, parallel, controlled trial evaluating repetitive transcranial magnetic stimulation (rTMS) for EF deficits in ASD. Method: In Toronto, Ontario (November 2014 to June 2017), a 20-session, 4-week course of 20 Hz rTMS targeting dorsolateral prefrontal cortex (DLPFC) (90%RMT) was compared to sham stimulation in 16–35 year-olds with ASD (28 male/12 female), without intellectual disability, who had impaired everyday EF performance (n = 20 active/n = 20 sham). Outcome measures evaluated protocol feasibility and clinical effects of active vs. sham rTMS on EF performance. The moderating effect of baseline functioning was explored. Results: Of eligible participants, 95% were enrolled and 95% of randomized participants completed the protocol. Adverse events across treatment arms were mild-to-moderate. There was no significant difference between active vs. sham rTMS on EF performance. Baseline adaptive functioning moderated the effect of rTMS, such that participants with lower baseline functioning experienced significant EF improvement in the active vs. sham group. Conclusions: Our pilot RCT demonstrated the feasibility and acceptability of using high frequency rTMS targeting DLPFC in youth and young adults with autism. No evidence for efficacy of active versus sham rTMS on EF performance was found. However, we found promising preliminary evidence of EF performance improvement following active versus sham rTMS in participants with ASD with more severe adaptive functioning deficits. Future work could focus on examining efficacy of rTMS in this higher-need population. Clinical trial registration: Repetitive Transcranial Magnetic Stimulation (rTMS) for Executive Function Deficits in Autism Spectrum Disorder and Effects on Brain Structure: A Pilot Study; https://clinicaltrials.gov/ct2/show/NCT02311751?term = ameis&rank = 1; NCT02311751. The trial was funded by: an American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award, the Innovation Fund from the Alternate Funding Plan of the Academic Health Sciences Centres of Ontario, and an Ontario Mental Health Foundation (OMHF) Project A Grant and New Investigator Fellowship.
AB - Background: In youth and young adults with autism spectrum disorder (ASD), executive function (EF) deficits may be a promising treatment target with potential impact on everyday functioning. Objective: To conduct a pilot randomized, double-blind, parallel, controlled trial evaluating repetitive transcranial magnetic stimulation (rTMS) for EF deficits in ASD. Method: In Toronto, Ontario (November 2014 to June 2017), a 20-session, 4-week course of 20 Hz rTMS targeting dorsolateral prefrontal cortex (DLPFC) (90%RMT) was compared to sham stimulation in 16–35 year-olds with ASD (28 male/12 female), without intellectual disability, who had impaired everyday EF performance (n = 20 active/n = 20 sham). Outcome measures evaluated protocol feasibility and clinical effects of active vs. sham rTMS on EF performance. The moderating effect of baseline functioning was explored. Results: Of eligible participants, 95% were enrolled and 95% of randomized participants completed the protocol. Adverse events across treatment arms were mild-to-moderate. There was no significant difference between active vs. sham rTMS on EF performance. Baseline adaptive functioning moderated the effect of rTMS, such that participants with lower baseline functioning experienced significant EF improvement in the active vs. sham group. Conclusions: Our pilot RCT demonstrated the feasibility and acceptability of using high frequency rTMS targeting DLPFC in youth and young adults with autism. No evidence for efficacy of active versus sham rTMS on EF performance was found. However, we found promising preliminary evidence of EF performance improvement following active versus sham rTMS in participants with ASD with more severe adaptive functioning deficits. Future work could focus on examining efficacy of rTMS in this higher-need population. Clinical trial registration: Repetitive Transcranial Magnetic Stimulation (rTMS) for Executive Function Deficits in Autism Spectrum Disorder and Effects on Brain Structure: A Pilot Study; https://clinicaltrials.gov/ct2/show/NCT02311751?term = ameis&rank = 1; NCT02311751. The trial was funded by: an American Academy of Child and Adolescent Psychiatry (AACAP) Pilot Research Award, the Innovation Fund from the Alternate Funding Plan of the Academic Health Sciences Centres of Ontario, and an Ontario Mental Health Foundation (OMHF) Project A Grant and New Investigator Fellowship.
KW - Autism
KW - Clinical trial
KW - Executive functioning
KW - Intervention
KW - Repetitive transcranial magnetic stimulation
KW - Youth
UR - http://www.scopus.com/inward/record.url?scp=85078462949&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85078462949&partnerID=8YFLogxK
U2 - 10.1016/j.brs.2020.01.007
DO - 10.1016/j.brs.2020.01.007
M3 - Article
C2 - 32289673
AN - SCOPUS:85078462949
SN - 1935-861X
VL - 13
SP - 539
EP - 547
JO - Brain Stimulation
JF - Brain Stimulation
IS - 3
ER -